Tesaro +7%, BMO sees "significant opportunity" for rolapitant

|About: Tesaro (TSRO)|By:, SA News Editor

Shares of Tesaro (TSRO +7%) are getting a boost from an upgrade by BMO Capital to Outperform from Perform along with a $10 PT hike to $46.

The firm cites meetings with management,  from which it came away seeing "a significant opportunity [...] for rolapitant within NCCN treatment guidelines" to the tune of peak sales of $400M.

Additional upside could come from "large contracts on rolapitant approval, IV development, and pipeline progress, particularly with PARP inhibitor niraparib."